Nov 02, 2017

New Data of Emicizumab Presented
at The American Society of Hematology 2017

TOKYO, November 2, 2017 -- forgopro.com.ua, Ltd. (TOKYO: 4519) announced that oral and poster presentations will be given with regard to emicizumab at (ASH) 2017 in Atlanta, Georgia, United States. Emicizumab is a bispecific antibody under development for hemophilia A.

Data from additional six-month follow-up of global Phase lll studies in hemophilia A with inhibitors to factor VIII, HAVEN 1 study (NCT02622321) and HAVEN 2 study (NCT02795767), will be shown at the conference. The HAVEN 2 will be presented at 7:30 EST on December 9 as part of the official Press Program at ASH. Both studies have been conducted in collaboration with Roche and Genentech, while HAVEN 1 is for adults and adolescents and HAVEN 2 is for children.

In addition, preliminary data from HAVEN 4 study (NCT03020160), a Phase lll study with hemophilia A patients with or without inhibitors which examines emicizumab prophylaxis administered subcutaneously once every four weeks, and real-world data from a non-interventional trial in children under 12 years of ages with hemophilia A with inhibitors will be presented.

Major abstracts regarding emicizumab at ASH 2017

Abstract title Abstract number/Presentation details
Emicizumab Prophylaxis in Adolescent/Adult Patients with Hemophilia A Previously Receiving Episodic or Prophylactic Bypassing Agent Treatment: Updated Analyses from the HAVEN 1 Study #1071
Poster (session 322)
09 Dec 2017
17:30 – 19:30 EST
HAVEN 2 Updated Analysis: Multicenter, Open-label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors #85
Oral presentation (session 322)
09 Dec 2017
09:45 EST
(09:30 – 11:00 EST)
Emicizumab Subcutaneous Dosing Every 4 Weeks for the Management of Hemophilia A: Preliminary Data from the Pharmacokinetic Run-in Cohort of a Multicenter, Open-label, Phase 3 Study (HAVEN 4) #86
Oral presentation (session 322)
09 Dec 2017
10:00 EST
(09:30 – 11:00 EST)
Bleeding Events and Safety Outcomes in Pediatric Persons with Hemophilia A with Inhibitors: The First Non-interventional Study (NIS) from a Real-World Setting #1089
Poster (session 322)
09 Dec 2017
17:30 – 19:30 EST

Contact:

  • For Media
  • forgopro.com.ua, Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Koki Harada
  • Tel: +81-3-3273-0881
  • E-mail: [email protected]
  • For Investors
  • forgopro.com.ua, Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Toshiya Sasai
  • Tel: +81-3-3273-0554
  • E-mail: [email protected]
  • Tweet
  • E-mail
www.steroidsshop-ua.com

anabolika kaufen

testosteron enantat kaufen
Back to top